Top

EJNMMI Research

Published in:

Open Access 01-12-2011 | Original research

Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after ¹⁷⁷Lu-DOTA-Tyr³-octreotate treatment: a histological study in xenografted mice

Authors: Ann Erlandsson, Eva Forssell-Aronsson, Tomas Seidal, Peter Bernhardt

Published in: EJNMMI Research | Issue 1/2011

Abstract

Background

Small-cell lung carcinoma (SCLC) is an aggressive malignancy characterised by an early relapse, a tendency towards drug resistance, and a high incidence of metastasis. SCLC cells are of neuroendocrine origin and express high levels of somatostatin receptors; therefore, future treatment might involve targeting tumours with radiolabelled somatostatin analogues. This therapy induces abundant necrotic patches that contain exposed keratins; thus, keratin 8, which is one of the most abundant cytoskeletal proteins may represent an interesting secondary target for SCLC. This study aimed to investigate the effects of¹⁷⁷Lu-DOTA-Tyr³-octerotate and the binding of the monoclonal anti-keratin 8 antibody, TS1, in vitro in treated SCLC- and midgut-xenografted mouse models.

Methods

NCI-H69- and GOT1-xenotransplanted mice were treated with three doses of 30 MBq¹⁷⁷Lu-DOTA-Tyr³-octreotate administered 24 h apart. Mice xenotransplanted with NCI-H69 were sacrificed 1, 5, 12, 20 and 150 days post-injection or when the tumour had regrown to its original size. GOT1-xenotransplanted mice were sacrificed 3 days post-injection. Immunohistochemistry was performed to evaluate TS1 staining in tumours and in seven human biopsies of primary SCLC from pulmonary bronchi. Central cell density and nucleus size were determined in NCI-H69 sections.

Results

Twelve days after¹⁷⁷Lu-DOTA-Tyr³-octerotate treatment, the SCLC xenograft response was extensive. Twenty days after treatment, one of three analysed tumours displayed complete remission. The other two tumours showed 1/4 the cell density of untreated controls and cell nuclei were about three times larger than those of untreated controls. At 150 days after treatment, one of four mice exhibited complete remission. Treated tumours displayed increased TS1 antibody accumulation and high TS1 binding in necrotic patches. All seven human SCLC biopsies displayed necrotic areas with TS1 staining.

Conclusions

Radiation treatment with three injections of 30 MBq¹⁷⁷Lu-DOTA-Tyr³-octreotate had pronounced effects on tumour cell density and cell nuclei, which indicated mitotic catastrophe. Despite these anti-tumour effects, two of three SCLC tumours recurred. Further studies should investigate the nature of tumour cell survival and develop more effective treatments. High TS1 accumulation in tumour sections in vitro after¹⁷⁷Lu-DOTA-Tyr³-octerotate treatment indicated that TS1 might represent a promising secondary therapeutic strategy.

Available only for authorised users

Stupp R, Monnerat C, Turrisi AT, Perry MC, Leyvraz S: Small cell lung cancer: state of the art and future perspectives. Lung Cancer 2004, 45: 105–17. 10.1016/j.lungcan.2003.12.006PubMedCrossRef

Rossi A, Maione P, Palazzolo G, Sacco PC, Ferrara ML, Falanga M, Gridelli C: New targeted therapies and small-cell lung cancer. Clin Lung Cancer 2008, 9: 271–9. 10.3816/CLC.2008.n.042PubMedCrossRef

Rodriguez E, Lilenbaum RC: Small Cell Lung cancer: Past, Present, and Future. Curr Oncol Rep 2010, 12: 327–34. 10.1007/s11912-010-0120-5PubMedCrossRef

Rekhtman N: Neuroendocrine Tumors of the Lung An Update. Arch Pathol Lab Med 2010, 134: 1628–38.PubMed

O'Byrne KJ, Schally AV, Thomas A, Carney DN, Steward WP: Somatstatin, its receptors and analogs, in Lung cancer. Chemotherapy 2001, 47:(Suppl 2):1878–1908.

Moll R, Franke WW, Schiller DL, Geiger B, Krepler R: The catalog of human cytokeratines: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982, 31: 11–24. 10.1016/0092-8674(82)90400-7PubMedCrossRef

Blobel GA, Gould VE, Moll R, Lee I, Huszar M, Geiger B, Franke WW: Coexpression of neuroendocrine markers and epithelial cytoskeletal proteins in bronchopulmonary neuroendocrine neoplasms. Lab Invest 1985, 52: 39–51.PubMed

Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008, 15: 504–14. 10.1038/sj.cdd.4402283PubMedCrossRef

Kitamura H, Okudela K, Yazawa T, Sato H, Shimoyamada H: Cancer stem cell: Implications in cancer biology and therapy with special reference to lung cancer. Lung Cancer 2009, 66: 275–81. 10.1016/j.lungcan.2009.07.019PubMedCrossRef

10.

Salcido CD, Larochelle A, Taylor NBJ, Dunbar CE, Varticovski L: Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br J Cancer 2010, 102: 1636–44. 10.1038/sj.bjc.6605668PubMedCentralPubMedCrossRef

11.

Brambilla E, Negoescu A, Gazzeri S, Lantuejoul S, Moro D, Brambilla C, Coll JL: Apoptosis-related factors p53, Bcl2 and Bax in neuroendocrine lung tumors. Am J Pathol 1996, 149: 1941–52.PubMedCentralPubMed

12.

Gemba K, Ueoka H, Kiura K, Tabata M, Harada M: Immunohistochemical detection of mutant p53 protein in small-cell lung cancer: relationship to treatment outcome. Lung Cancer 2000, 29: 23–31.PubMedCrossRef

13.

Jiang SX, Sato Y, Kuwao S, Kameya T: Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 1995, 177: 135–8. 10.1002/path.1711770206PubMedCrossRef

14.

Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, Lin X, Hierman JS, Wilburn DL, Watkins DN, Rudin CM: Therapeutic efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer. Cancer Res 2008, 68: 2321–8. 10.1158/0008-5472.CAN-07-5031PubMedCentralPubMedCrossRef

15.

Kwekkeboom DJ, Kho GS, Lamberts SW, Reubi JC, Laissue JA, Krenning EP: The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994, 21: 1106–13.PubMedCrossRef

16.

Forssell-Aronsson E, Bernhardt P, Nilsson O, Tisell LE, Wängberg B, Ahlman H: Biodistribution data from 100 patients i.v. injected with 111In-DTPA-D-Phe1-octreotide. Acta Oncol 2004, 43: 436–42. 10.1080/02841860410030670PubMedCrossRef

17.

Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kölby L, Schmitt J, Forssell-Aronsson E: Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother Radiopharm 2003, 18: 593–9. 10.1089/108497803322287682PubMedCrossRef

18.

Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kölby L, Maecke HR, Forssell-Aronsson E: Radiation therapy of small cell lung cancer with¹⁷⁷ Lu-DOTA-Tyr³ -octreotate in an animal model. J Nucl Med 2004, 45: 1542–48.PubMed

19.

Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kölby L, Forssell-Aronsson E: Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model. Cancer Biother Radiopharm 2005, 20: 231–6. 10.1089/cbr.2005.20.231PubMedCrossRef

20.

Pless M, Waldherr C, Maecke H, Buitrago C, Herrmann R, Mueller-Brand J: Targeted radiotherapy for small cell lung cancer using 90yttrium-DOTATOC, an yttrium-labelled somatostatin analogue: a pilot trial. Lung Cancer 2004, 45: 365–71. 10.1016/j.lungcan.2004.02.020PubMedCrossRef

21.

van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, Wolbers JG, Kwekkeboom DJ: Effects of therpy with [¹⁷⁷ Lu-DOTA⁰ Tyr³ ]Octreotate in Patients with Paraganglioma, Meningioma, Small Cell Lung Carcinoma, and Melanoma. J Nucl Med 2006, 47: 1599–1606.PubMed

22.

de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP: [177Lu-DOTA(0),Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001, 92: 628–33. 10.1002/1097-0215(20010601)92:5<628::AID-IJC1244>3.0.CO;2-LPubMedCrossRef

23.

Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, de Jong M, Srinivasan A, Erion JL, Krenning EP: Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003, 30: 417–22. 10.1007/s00259-002-1050-8PubMedCentralPubMedCrossRef

24.

Zhao R, Yang W, Wang Z, Li G, Qin W, Wang J: Treatment of transplanted tumor of lung adenocarcinoma A549 transfected by human somatostatin receptor subtype 2 (hsstr2) gene with¹⁸⁸ Re-RC-160. Nucl Med Biol 2010, 37: 977–87. 10.1016/j.nucmedbio.2010.05.007PubMedCrossRef

25.

Bernhardt P, Benjegård SA, Kölby L, Johanson V, Nilsson O, Ahlman H, Forssell-Aronsson E: Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. Int J Radiat Oncol Biol Phys 2001, 51: 514–24. 10.1016/S0360-3016(01)01663-7PubMedCrossRef

26.

Bernhardt P, Ahlman H, Forssell-Aronsson E: Model of metastatic growth valuable for radionuclide therapy. Med Phys 2003, 12: 3227–32.CrossRef

27.

Kölby L, Bernhardt P, Johanson V, Schmitt A, Ahlman H, Forssell-Aronsson E, Mäcke H, Nilsson O: Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour. Br J Cancer 2005, 93: 1144–51. 10.1038/sj.bjc.6602845PubMedCentralPubMedCrossRef

28.

Oddstig J, Bernhardt P, Nilsson O, Ahlman H, Forssell-Aronsson : Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro . Nucl Med Biol 2006, 33: 841–6. 10.1016/j.nucmedbio.2006.07.010PubMedCrossRef

29.

Melis M, Forrer F, Capello A, Bijster M, Bernard BF, Reubi JC, Krenning EP, De Jong M: Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [¹⁷⁷ Lu-DOTA⁰ , Tyr³ ]octreotate therapy. Q J Nucl Med Mol Imaging 2007, 51: 324–33.PubMed

30.

Sundström B, Johansson B, Hietala SO, Stigbrand T: Radio-immunolocalization in nude mice using anticytokeratin monoclonal antibodies. Tumour Biol 1990, 11: 158–66. 10.1159/000217650PubMedCrossRef

31.

Johansson A, Eriksson D, Ullén A, Löfroth PO, Johansson L, Riklund-Ahlström K, Stigbrand T: The combination of external beam radiotherapy and experimental radioimmunotargeting with a monoclonal anticytokeratin antibody. Cancer 2002, 94: 1314–9. 10.1002/cncr.10302PubMedCrossRef

32.

Eriksson D, Joniani HM, Sheikholvaezin A, Löfroth PO, Johansson L, Riklund Ahlström K, Stigbrand T: Combined low dose radio- and radioimmunotherapy of experimental HeLa Hep 2 tumours. Eur J Nucl Med Mol Imaging 2003, 30: 895–906. 10.1007/s00259-003-1177-2PubMedCrossRef

33.

Hendrix MJ, Seftor EA, Chu YW, Trevor KT, Seftor RE: Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev 1996, 15: 507–25. 10.1007/BF00054016PubMedCrossRef

34.

Hembrough TA, Li L, Gonias SL: Cell-surface Cytokeratin 8 is the Major Plasminogen Receptor on breast Cancer Cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. J Biol Chem 1996, 271: 25684–91. 10.1074/jbc.271.41.25684PubMedCrossRef

35.

Modjtahedi N, Frebourg T, Fossar N, Lavialle C, Cremisi C, Brison O: Increased expression of cytokeratin and ferritin-H genes in tumorigenic clones of the SW 613-S human colon carcinoma cell line. Exp Cell Res 1992, 201: 74–82. 10.1016/0014-4827(92)90349-DPubMedCrossRef

36.

Johansson A, Sandström P, Ullén A, Behravan G, Erlandsson A, Levi M, Sundström B, Stigbrand T: Epitope specificity of the monoclonal antibody TS1. Cancer Res 1999, 59: 48–51.PubMed

37.

Kölby L, Bernhardt P, Ahlman H, Wängberg B, Johanson V, Wigander A, Forssell-Aronsson E, Karlsson S, Ahrén B, Stenman G, Nilsson O: A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am J Pathol 2001, 158: 745–55. 10.1016/S0002-9440(10)64017-5PubMedCentralPubMedCrossRef

38.

Bernhardt P, Oddstig J, Kölby L, Nilsson O, Ahlman H, Forssell-Aronsson E: Effects of treatment with (177)Lu-DOTA-Tyr(3)-octreotate on uptake of subsequent injection in carcinoid-bearing nude mice. Cancer Biother Radiopharm 2007, (22):644–53.

39.

Sundström BE, Nathrath WB, Stigbrand TI: Diversity in immunoreactivity of tumor-derived cytokeratin monoclonal antibodies. J Histochem Cytochem 1998,37(suppl 12):1845–54.

40.

Preibisch S, Saalfeld S, Tomancak P: Globally optimal stitching of tiled 3D microscopic image acquisitions. Bioinformatics 2009, 25: 1463–5. 10.1093/bioinformatics/btp184PubMedCentralPubMedCrossRef

41.

Stigbrand T, Carlsson J, Gregory PA: Targeted radionuclide Tumor Therapy Biological aspects. 1st edition. Springer Science; 2008.CrossRef

42.

Grassi A, Susca M, Ferri S, Gabusi E, D'Errico A, Farina G, Maccariello S, Zauli D, Bianchi FB, Ballardini G: Detection of the M30 neoepitope as a new tool to quantify liver apoptosis: timing and patterns of positivity on frozen and paraffin-embeded sections. Am J Clin Pathol 2004, 121: 211–9. 10.1309/UK621LFJ4FX07KDEPubMedCrossRef

43.

Omary MB, Ku NO, Liao J, Price D: Keratin modifications and solubility properties in epithelial cells in vitro . Subcell Biochem 1998, 31: 105–40.PubMed

44.

Zhao J, Gao F, Zhang Y, Wei K, Deng X: Bcl2 Inhibits Abasic Site repair by down-regulating APE1 Endonuclease Activity. J Biol Chem 2008, 283: 9925–32. 10.1074/jbc.M708345200PubMedCentralPubMedCrossRef

45.

Eriksson D, Löfroth PO, Johansson L, Riklund KA, Stigbrand T: Cell cycle disturbances and mitotic catastrophes in HeLa Hep2 cells following 2.5 to 10 Gy of ionizing radiation. Clin Cancer Res 2007, 13: 5501–8. 10.1158/1078-0432.CCR-07-0980CrossRef

46.

Erenpreisa J, Cragg MS: Mitotic death: a mechanism of survival? A review. Cancer Cell Int 2001, 1: 1–7. 10.1186/1475-2867-1-1PubMedCentralPubMedCrossRef

47.

Vakifahmetoglu H, Olsson M, Tamm C, Heidari N, Orrenius S, Zhivotovsky B: DNA damage induces two distinct modes of cell death in ovarian carcinomas. Cell Death Differ 2008, 15: 555–66. 10.1038/sj.cdd.4402286PubMedCrossRef

48.

Mansilla S, Priebe W, Portugal J: Mitotic catastrophe results in cell death by caspase-dependent and caspase independent mechanisms. Cell Cycle 2006, 5: 53–60. 10.4161/cc.5.1.2267PubMedCrossRef

49.

Salmina K, Jankevics E, Huna A, Perminov D, Radovica I, Klymenko T, Ivanov A, Jascenko E, Scherthan H, Cragg M, Erenpreisa J: Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells. Exp Cell Res 2010, 316: 2099–112. 10.1016/j.yexcr.2010.04.030PubMedCrossRef

50.

Norrlund RR, Ullén A, Sandström P, Holback D, Johansson L, Stigbrand T, Hietala SO, Riklund Ahlström K: Experimental radioimmunotargeting combining nonlabeled, iodine-125-labeled, and anti-idiotypic anticytokeratin monoclonal antibodies: a dosimetric evaluation. Cancer 1997, 80: 2689–98. 10.1002/(SICI)1097-0142(19971215)80:12+<2689::AID-CNCR47>3.0.CO;2-5CrossRef

51.

Jafari R, Holm P, Sandegren J, Stigbrand T, Sundström BE: Localization of complexed anticytokeratin 8 scFv TS1–218 to HeLa HEp-2 multicellular tumor spheroids and experimental tumors. Cancer Biother Radiopharm 2010, 25: 455–63. 10.1089/cbr.2010.0785PubMedCrossRef

52.

Jafari R, Holm P, Piercecchi M, Sundström BE: Construction of divalent anti-keratin 8 single-chain antibodies (sc(Fv)(2)), expression in Pichia pastoris and their reactivity with multicellular tumor spheroids. J Immunol Methods 2011, 364: 65–76. 10.1016/j.jim.2010.11.003PubMedCrossRef

Title: Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after 177Lu-DOTA-Tyr3-octreotate treatment: a histological study in xenografted mice
Authors: Ann Erlandsson
Eva Forssell-Aronsson
Tomas Seidal
Peter Bernhardt
Publication date: 01-12-2011
Publisher: Springer Berlin Heidelberg
Published in: EJNMMI Research / Issue 1/2011
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/2191-219X-1-19

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after ¹⁷⁷Lu-DOTA-Tyr³-octreotate treatment: a histological study in xenografted mice

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Comparison between 68Ga-bombesin (68Ga-BZH3) and the cRGD tetramer 68Ga-RGD4 studies in an experimental nude rat model with a neuroendocrine pancreatic tumor cell line

Use of [18F]FDOPA-PET for in vivo evaluation of dopaminergic dysfunction in unilaterally 6-OHDA-lesioned rats

18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)

Transbilayer phospholipids molecular imaging

Brain perfusion CT compared with15O-H2O-PET in healthy subjects

Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers